Specialty Hub

In-depth learning materials and relevant resources by areas of interest.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

In this section

Cardiology

Assorted resources on conditions connected to Cardiology.

Dermatology

Latest information on diseases in Dermatology.

Endocrinology

A detailed look at conditions connected to Endocrinology.

Gastroenterology and Hepatology

In-depth material on Gastroenterology and Hepatology.

Haematology

Assorted resources on conditions connected to Haematology.

Infectious Diseases

A detailed look at conditions connected to Infectious Diseases.

Neurology (CNS) and Pain

Learning materials and guidelines on Neurology (CNS) and Pain.

Oncology

A detailed look at conditions connected to Oncology.

Respiratory

In-depth material on Respiratory conditions.

Rheumatology

Latest information on diseases in Rheumatology.

Urology

Learning materials and guidelines on Urology.

Latest news

News

DCGI (India) approves Sputnik V COVID 19 vaccine for emergency use in India.- Dr Reddy's Laboratories

Dr. Reddy’s Laboratories Ltd. announced that it has received the permission from the Drug Controller General of India (DCGI) to import the Sputnik vaccine into India for restricted use in emergency situations as per the provisions of the New Drug and Clincial Trials rules, 2019 under the Drugs and Cosmetics Act.

1 mins

News

New integrated data and follow-up outcomes From Two Tepezza pivotal trials published in The Lancet Diabetes & Endocrinology.- Horizon Therapeutics

Horizon Therapeutics plc announced that new pooled data from the Tepezza (teprotumumab-trbw) Phase II and Phase III clinical trials are now published in The Lancet Diabetes & Endocrinology.

3 min

News

New long-term data for Uplizna in people living with neuromyelitis optica spectrum disorder.-Viela Bio/Horizon Therapeutics.

Horizon Therapeutics announced new Uplizna (inebilizumab-cdon) data being presented at the American Academy of Neurology’s 73rd Annual Meeting being held virtually April 17-22, 2021 (AAN 2021), including new, end-of-study data from the open-label extension period of the pivotal N-MOmentum trial in patients with NMOSD (neuromyelitis optica spectrum disorder).

2 min

See all news

You may be interested in...

Journal

Allele-Specific Knockout by CRISPR/Cas to Treat Autosomal Dominant Retinitis Pigmentosa Caused by the G56R Mutation in NR2E3

Retinitis pigmentosa (RP) is an inherited retinal dystrophy that causes progressive vision loss. The G56R mutation in NR2E3 is the second most common mutation causing autosomal dominant (ad) RP, a transcription factor that is essential for photoreceptor development and maintenance.

Journal

Clinical Characteristics, Differential Diagnosis and Genetic Analysis of Concentric Retinitis Pigmentosa

Concentric retinitis pigmentosa (RP), in which retinal degeneration is limited in the periphery, is rare and little information exists to date on the subject. Herein, we describe the clinical and genetic characteristics of this atypical form of RP.

Journal

Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR

In the present study, we report the first-in-human phase 1/2, dose-escalation clinical trial for X-linked RP caused by mutations in the RP GTPase regulator (RPGR) gene in 18 patients over up to 6 months of follow-up.